<DOC>
	<DOCNO>NCT02461290</DOCNO>
	<brief_summary>The primary objective evaluate safety profile tolerability rituximab combination different chemotherapy regimen .</brief_summary>
	<brief_title>Rituximab Therapy Follicular Lymphoma Combination With Chemotherapy - REFLECT 1</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>New diagnose Stage III/IV NHLs Grades 1 , 2 follicular lymphoma need treat mCD20 positive Have expect survival 3 month ECOG 02 grade Normal renal function ALT less double normal level Presence CNS lymphoma Severe infectious disease organic disease Having another malignant tumor Pregnant breastfeed female Organic heart disease , heart failure , II high grade AV bundle block . Subject allergic Rituximab Known HIV infection chronic HBV infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>